People · Operator
Named in public records as an officer, director or promoter · active 2019–2019 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Finch Therapeutics Group, Inc. | — | Biotechnology | Series C | $179.9M | $3.5B | 2019 |
Alan A. Gross at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Alan A. Gross on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mark Smith | 1 | 28 |
| James Burgess | 1 | 5 |
| Andrew Noh | 1 | 2 |
| Chris Lange | 1 | 2 |
| Zain Kassam | 1 | 2 |
| Benjamin Enerson | 1 | 1 |
| Andrew Mulderry | 1 | 1 |
| Greg A. Perry | 1 | 1 |
| Ulrich A. Thienel | 1 | 1 |
| R. J. Price | 1 | 1 |
| Domenic Ferrante | 1 | 1 |
| Jo A. Viney | 1 | 1 |
| Jeffery A. Smisek | 1 | 1 |
| Christopher A. Cosmides | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.